Drug Development/R&D

The Structural Genomics Consortium Oxford, University of Oxford, in collaboration with OHE (Prof Adrian Towse) and Dr Jorge Mestre-Ferrandiz, is recruiting for a Postdoctoral Position in “The Economics of life sciences’ R&D”.

In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for the Next Decade. The lecture is now available as a publication, available for download.

Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies.

OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This research looked at the health, economic and scientific impact of Oxford BRC’s research activity.

Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive.

Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the 2016 ICER Membership Policy Summit.

The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”. Several members of the OHE team attended and contributed to the conference; this post summarises their activity.

On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned by the Pharmaceutical Oncology Initiative (POI) as part of a wider research project being undertaken by OHE.

This study provides an analytical framework, drawing on production function theory, to identify and quantify the determinants of relative effectiveness and sources of variation in the relative effectiveness of treatments between populations and healthcare systems.

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines

Pages

Subscribe to RSS - Drug Development/R&D